Pharmaceuticals in the environment - A human risk?

Regulatory Toxicology and Pharmacology

Volumn 28, Issue 3, 1998, Pages 212-221

  Christensen, F M ^a  

^a DHI   (Denmark)

Author keywords

17 ethinylestradiol; CP; Cyclophosphamide; Drugs; EE2; Environment; EUSES; Exposure; Human health; Pen V; Pharmaceuticals; Phenoxymethylpenicillin; Risk assessment

Indexed keywords

CYCLOPHOSPHAMIDE; DRUG; ETHINYLESTRADIOL; PENICILLIN V;

ARTICLE; BIOACCUMULATION; BIODEGRADATION; DENMARK; DRUG APPROVAL; DRUG CONTROL; DRUG EXPOSURE; DRUG USE; ENVIRONMENTAL EXPOSURE; HUMAN; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; SEWER OUTFALL;

EID: 0032459770     PISSN: 02732300     EISSN: None     Source Type: Journal    
DOI: 10.1006/rtph.1998.1253     Document Type: Article

References (72)

1. Aherne G. W., English J., Marks V. The role of immunoassay in the analysis of microcontaminants in water samples. Ecotoxicol. Environ. Saf. 9:1985;79-83.
2. Bager, F. 1997, Consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, food and humans in Denmark, Danish Veterinary Laboratory, Copenhagen.
3. Bagley C. M., Bostick F. W., DeVita V. T. Jr. Clinical pharmacology of cyclophosphamide. Cancer Res. 33:1973;226-233.
4. Berger K., von Petersen B., Büning-Pfaue H. Persistenz von Gülle-Arzneistoffen in der Nahrungskette. Arch. Lebensmittelhyg. 37:1986;99-102.
5. Bergink E. W., Kloosterboer H. J., van der Velden W. H. M., van der Vies J., de Winter M. S. Specificity of an estrogen binding protein in the human vagina compared with that of estrogen receptors in different tissues from different species. Progress in Cancer Research and Therapy, Steroids and Endometrical Cancer. 1983;Raven Press, New York. p. 77-84.
6. Bolt H. M. The metabolic fate of mestranol and ethinylestradiol in humans. J. Steroid Biochem. 5:1974;320-321.
7. Bolt H. M., Kappus H., Käsbohrer R. Metabolism of 17α-ethinylestradiol by human liver microsomesin vitro: J. Clin. Endocrinol. Metab. 39:1974;1072-1080.
8. Bolt H. M. Metabolism of estrogens, natural and synthetic. Pharmacol. Ther. 4:1979;155-181.
9. Cheskis, B. 1997, Women's Health Research Institute, Wyeth-Ayerst Research, Radnor, PA.
10. Cohen J. L., Jao J. Y., Jusko W. J. Pharmacokinetics of cyclophosphamide in man. Br. J. Pharmacol. 43:1971;677-680.
11. Cole M., Kenig M. D., Hewitt V. A. Metabolism of penicillins to penicilloic acids and 6-aminopenicillanic acid in man and its significance in assessing penicillin absorption. Antimicrob. Agents Chemother. 3:1973;463-468.
12. CPMP, 1996, IIB, Commission of the European Union.
13. CVMP, 1997a, The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines Evaluation Unit, London.
14. CVMP, 1997b, The European Agency for the Evaluation of Medicinal Products, Veterinary Medicines Evaluation Unit, London.
15. Danmarks Statistik, 1997, Danish Statistics, Copenhagen.
16. EC, 1997.
17. EC-EUSES, 1996.
18. EC-TGD, 1996, Office for Official Publications of the European Community, Luxembourg.
19. Ensslin A. S., Stoll Y., Pethran A., Pfaller A., Römmelt H., Fruhmann G. Biological monitoring of cyclophosphamide and ifosfamide in urine of hospital personnel occupationally exposed to cytostatic drugs. Occup. Environ. Med. 51:1994;229-233.
20. EpiWin, 1995.
21. EU, 1994a, European Commission, Brussels.
22. EU, 1994b, European Commission, Brussels.
23. Farber T. M., Arcos M. A regulatory approach to the use of anabolic agents. Meissonnier E. Anabolics in Animal Production. 1983;289-296 Office International des Epizooties, Paris.
24. FDA, 1995, Guidance for industry for the submission of an environmental assessment in human drug applications and supplements, Food and Drug Administration.
25. FDA, 1996a, Center for Drug Evaluation and Research, Food and Drug Administration.
26. FDA, 1996b, Center for Drug Evaluation and Research, Food and Drug Administration.
27. Fotsis T., Adlercreutz H. The multicomponent analysis of estrogens in urine by ion exchange chromatography and GC-MS - I. Quantification of estrogens after initial hydrolysis of conjugates. J. Steroid Biochem. 28:1987;203-213.
28. Fotsis T., Järvenpää P., Adlercreutz H. Purification of urine for quantification of the complete estrogen profile. J. Steroid Biochem. 12:1980;503-508.
29. Fredenslund, F. C. Severinsen, M. Andersen, M. B. 1995, Evaluation of the SimpleBox Model for Danish Conditions. Technical Report No. 1 to "Environmental Exposure Assessment of Chemicals" Danish Environmental Protection Agency, Copenhagen.
30. Griffin J. E. Male reproductive function. Griffen J. E., Ojeda S. R. Textbook of Endocrine Physiology. 1996;Oxford Univ. Press, Oxford.
31. Halling-Sørensen B., Nielsen S. N., Lanzky P. F., Ingerslev F., Lützhøft H. C. H., Jørgensen S. E. Occurrence, fate and effects of pharmaceutical substances in the environment - A review. Chemosphere. 36:1998;357-395.
32. Hardman J. G., Limbird L. E. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 1996;McGraw-Hill.
33. Helton E. D., Williams M. C., Goldzieher J. W. Human urinary and liver conjugates of 17α-ethinylestradiol. Steroids. 27:1976;851-867.
34. Henschel K-P., Wenzel A., Diedrich M., Fliedner A. Environmental hazard assessment of pharmaceuticals. Regul. Toxicol. Pharmacol. 25:1997;220-225.
35. HSDB (Hazardous Substances Data Bank).
36. IARC, 1981, 26, IARC, World Health Organization, Lyon.
37. Juul, K. V. 1997, Forbruget af p-piller, Danish Medicine Agency, Copenhagen.
38. Kalbfus W. Belastung bayerischer Gewässer durch synthetische Östrogene. Stoffe mit endokriner Wirkung im Wasser. 1997;Oldenbourg Verlag, Münich. p. 31-38.
39. Kaspar P., Witzel H. Steroid binding of the cytosolic estrogen receptor from rat uterus. Influence of the orientation of substituents in the 17-position of the 8β- and 8α-series. J. Steroid Biochem. 23:1985;259-265.
40. Kieth, L. H. Walters, D. B. 1992, The National Toxicology Program - Chemical data compendium, II.
41. Kristensen M. B., Friis H., Rassing M. R. Lægemiddelkataloget 1995. 1995;Dansk EDB Satscentrum A/S, Copenhagen.
42. 14. Contraception. 1:1970;47-55.
43. Kümmerer K., Steger-Hartmann T., Baranyai A., Bürhaus I. Prühfung des biologischen Abbaus der Zytostatika Cyclophosphamid und Ifosfamid mit dem Closed Bottle Test (OECD 301 D). Zbl. Hyg. 198:1996;215-225.
44. Lægemiddelstyrelsen, 1996, Lægemiddelstatistik 1995 Danmark, Schultz Erhvervsboghandel, Copenhagen.
45. Lægemiddelstyrelsen, 1997.
46. 3. Xenobiotica. 13:1983;421-431.
47. Matney T. S., Nguyen T. V., Connor T. H., Dana W. J., Theiss J. C. Genotoxic classification of anticancer drugs. Teratogen. Carcinog. Mutagen. 5:1985;319-328.
48. Vejledning fra Miljøstyrelsen, No. 6. 1990.
49. Vejledning fra Miljøstyrelsen, No. 1. 1992.
50. Murín M., Gavora J., Drastichova I., Duskova E., Madsen T., Tørsløv J., Damborg A., Tyle H., Pedersen F. Aquatic hazard and risk assessment of two selected substances produced in high volumes in the Slovak republic. Chemosphere. 34:1997;179-190.
51. Norpoth K., Nehrkorn A., Kirchner M., Holsen H., Teipel H. Untersuchungen zur Frage der Löslichkeit und Stabilität ovulationshemmender Steroide in Wasser, Abwässern und Belebtschlamm. Zbl. Bakt. Hyg. I. Abt. Orig. B. 156:1973;500-511.
52. Park B. K., Maggs J. L. Inter-individual variation in the metabolism of ethinylestradiol. Prog. Clin. Biol. Res. 214:1986;289-302.
53. Purdom C. E., Hardiman P. A., Bye V. J., Eno N. C., Tyler C. R., Sumpter J. P. Estrogenic effects of effluents from sewage treatment works. Chem. Ecol. 8:1994;275-285.
54. Raeside J. I., Liptrap R. M. Patterns of urinary oestrogen excretion in individual pregnant mares. J. Reprod. Fertil. 1975;469-475.
55. Rathner M., Sonnenborn M. Biologisch Wirksame Östrogene in Trink- und Abwasser. Sonderheft: Direktor Prof. Dr. Med. Gertrud Müller 60 Jahre. Forum Städte-hygiene. 30:1979;45-49.
56. Reynolds J. E. F. Martindale: The Extra Pharmacopoeia. 1982;Pharmaceutical Press, London.
57. Rurainski R. D., Thesis H. J., Zimmermann W. Über das Vorkommen von natürlichen und synthetischen Östrogenen im Trinkwasser. Gwf-wasser/abwasser. 118:1977;288-291.
58. Römbke J., Knacker T., Stahlschmidt-Allner P. Umweltprobleme durch Arzneimittel - Literaturstudie. ECT Oekotoxikologie GmbH. UBA Texte. Berichtsnummer UBA-FB 96-060. 1996.
59. Schmäll D. Cancerogen wirkende Arzneimittel. Schmähl D. Maligne Tumoren - Entstehung, Wachstum und Chemotherapie. 1981;203-220 Editio Cantor, Aulendorf.
60. Shore L. S., Gurevitz M., Shemesh M. Estrogen as an environmental pollutant. Bull. Environ. Contam. Toxicol. 51:1993;361-366.
61. Stambrugskontoret, 1997, Landsudvalget for heste. Årsberetning for stambrugsføring for landskoret for heste, Aarhus, Denmark.
62. Steger-Hartmann, T. 1995, Analytik und Ökotoxicologie klinikspezifischer Abwasserinhaltsstoffe mit Schwerpunkt auf die Zytostatika Cyclophosphamid und Ifosfamid, Fakultät für Biologie der Albert-Ludwigs-Universität, Freiburg.
63. Steger-Hartmann T., Kümmerer K., Hartmann A. Biological degradation of cyclophosphamide and its occurrence in sewage water. Ecotoxicol. Environ. Saf. 36:1997;174-179.
64. Sumpter J. P. Reproductive effects from oestrogen activity in polluted water. Seiler J. P., Autrup H., Autrup J. L. Archives of Toxicology: Supplement 20. Diversification in Toxicology: Man and Environment; Proceedings of the 1997 EUROTOX Congress Meeting Held in Aarhus, Denmark, June 25-28, 1997. 1997;143-150 Springer-Verlag, Berlin, Heidelberg.
65. Tabak H. H., Bunch R. L. Steroid hormones as water pollutants. Society for Industrial Microbiology. Developments in Industrial Biology. Volume 11. Proceedings of the Twenty-Sixth General Meeting of the Society for Industrial Microbiology Held in Burlington, Vermont, August 17-22, 1969. 1970;367-376 Am. Inst. Biol. Sci. Washington.
66. Tabak H. H., Bloomhuff R. N., Bunch R. L. Steroid hormones as water pollutants. II. Studies on the persistence and stability of natural urinary and synthetic ovulation-inhibiting hormones in untreated and treated wastewaters. Society for Industrial Microbiology. Developments in Industrial Microbiology. Volume 22. Proceedings of the Thirty-Seventh General Meeting of the Society for Industrial Microbiology Held at Flagstaff, Arizona, August 9-15, 1980. 1981;497-519.
67. An Encyclopaedia of Chemicals, Drugs and Biologicals. 1989;Merck, Rahwey.
68. Turan A. Exkretion Natürlicher und syntetischer Östrogene und ihrer Metabolite: Vorkommen und Verhalten im Wasser. UBA-texte 65/95. 1995;16-21.
69. Tønnesen, H. 1997, H:S Pharmacy, Department of Clinical Pharmacy, Copenhagen, Denmark.
70. Verschueren K. Handbook of Environmental Data on Organic Chemicals. 1996;Van Nostrand Reinhold.
71. WHO, 1995, Anatomical Therapeutic Chemical (ATC) Classification Index - Including Defined Daily Doses (DDDs), WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway.
72. Zeise L., Wilson R., Crouch E. C. Dose-response relationships for carcinogenesis: A review. Environ. Health Perspect. 73:1987;259-308.